C7a Compound Helps Fight Adult T Cell Leukemia
Author Information
Author(s): Guimaraes-Correa Ana B., Crawford Lindsey B., Figueiredo Carlos R., Gimenes Karina P., Pinto Lorena A., Rios Grassi Maria Fernanda, Feuer Gerold, Travassos Luiz R., Caires Antonio C.F., Rodrigues Elaine G., Marriott Susan J.
Primary Institution: Universidade Federal de São Paulo (UNIFESP-EPM)
Hypothesis
Can the biphosphinic cyclopalladated compound C7a effectively treat adult T cell leukemia/lymphoma (ATLL) in a patient-derived xenograft model?
Conclusion
C7a significantly increases survival in mice with ATLL and induces apoptosis in human T cell leukemia lines.
Supporting Evidence
- C7a increased survival in RV-ATL engrafted mice compared to untreated controls.
- C7a induced apoptosis in both HTLV-1 infected and uninfected T cell lines.
- C7a did not harm healthy human blood cells while effectively targeting cancer cells.
Takeaway
A special compound called C7a can help sick mice live longer when they have a type of blood cancer called ATLL.
Methodology
The study used a patient-derived xenograft model in immunocompromised mice to test the effects of C7a on ATLL.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Statistical Information
P-Value
0.049
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website